BioHarvest Sciences Inc
BioHarvest Sciences Inc. develops Botanical Synthesis technology for producing plant-based molecules and commercial ingredients. The company operates through a corporate group with roots in Israel and Canada, and its activities span research, manufacturing, and contract development and manufacturing relationships for specialty molecules and consumer ingredients.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueCore proprietary platform used to produce plant-based molecules and ingredients.
Development and manufacturing services for partner companies and programs.
Custom fragrance-related molecule development and supply programs.
Plant-based consumer and wellness ingredients sold through operating subsidiaries.
Customers
BioHarvest sells to commercial partners that need specialty molecules, development support, or future supply capacity rather than broad mass-market consumers. The company also serves end-market buyers in premium fragrance and plant-based nutrition, where customers value scalable, sustainable ingredient production and technical differentiation.
Buy custom botanical molecules for premium fragrance programs and future supply agreements.
Use BioHarvest for development, scale-up, and manufacturing of specialty molecules.
Buy plant-based ingredients and products for wellness and consumer formulations.
Enter staged contracts to validate technology and support eventual commercialization.
Strategy
BioHarvest’s strategy centers on scaling its Botanical Synthesis platform into repeatable commercial programs that can support partner-driven development and manufacturing. The company is also building toward royalty-driven economics by converting technical validation into longer-duration supply and commercialization relationships, particularly in premium fragrance and other specialty ingredient markets.
Premium fragrance is a high-value end market that can validate the platform and generate repeat orders.
Larger production capability is needed to support commercial supply and broader customer programs.
A broader customer base reduces concentration and improves platform utilization.
Geography
BioHarvest generates revenue in North America and Israel, with North America representing the larger share of recent reported revenue. The company is headquartered in Vancouver, maintains operations and subsidiaries in Israel, and also has access to European listing and investor markets through foreign trading venues.
Risks
BioHarvest depends on successful technology scale-up, customer conversion, and timely facility expansion to turn development programs into durable revenue. It also faces execution risk typical of specialty biotech/manufacturing models, including customer concentration, development delays, and the possibility that commercial demand for novel ingredients develops more slowly than planned.
- Technology scale-up failureImpact: HighLikelihood: Medium
The business must move from development success to repeatable production at commercial scale.
Exposure: Botanical Synthesis and CDMO programs
- Customer and program concentrationImpact: HighLikelihood: Medium
Revenue can depend on a limited number of contracts and development milestones.
Exposure: Fragrance and partner programs
- Manufacturing capacity timingImpact: MediumLikelihood: Medium
Commercial supply depends on new facility commissioning and production readiness.
Exposure: New production facility
- Market adoption riskImpact: MediumLikelihood: Medium
Novel plant-based molecules must gain traction against established sourcing methods.
Exposure: Premium fragrance and specialty ingredients
Accounting
Judgemental itemsContracts and staged commercialization programs can shift revenue timing across quarters.
Impact: Affects quarterly comparability and reported growth
Scale-up manufacturing requires valuation of inventory and equipment under production ramp conditions.
Impact: Can affect gross margin and asset carrying values
The company uses leased facilities and recognizes right-of-use assets and lease liabilities.
Impact: Affects EBITDA-like measures and balance sheet leverage
R&D support programs can reduce net development expense if recognition criteria are met.
Impact: Can materially offset reported R&D spending
Similar listed companies
Publicly listed companies with a comparable business focus.
NovelStem International Corp.
NSTM · Retail-Retail Stores, NEC
Impact BioMedical, Inc
IBO · Pharmaceutical Preparations
Codexis, Inc
CDXS · Industrial Organic Chemicals
Evogene Ltd.
EVGN · Agricultural Chemicals
IM Cannabis Corp.
IMCC · Medicinal Chemicals & Botanical Products
Pelthos Therapeutics Inc.
PTHS · Biological Products, (No Diagnostic Substances)
Last updated: 28/09/2026